Prospective Multiomic Analysis in Small-Cell Lung Cancer

The goal of this study is to prospectively and longitudinally collect blood and tumor tissue from patients with relapsed small cell lung cancer (SCLC) receicing standard of care commercial DLL3 T cell engager. We will do a comprehensive multi-omic analysis integrating genomic, transcriptomic, proteomic, and clinical data to investigate mechanisms of resistance, and identify potential therapeutic vulnerabilities.

Primary objective is to assess the feasibility of obtaining paired tumor samples and serial blood collection in relapsed ES-SCLC patients

Secondary objectives are to characterize longitudinal SCLC tumor-associated markers, including DLL3; evaluate concordance between plasma and tissue, ctDNA, protomics and explore associations between molecular findings and clinical outcomes.

Inclusion criteria

• 18 years of age or older
• Confirmed pathologic diagnosis of active SCLC or neuroendocrine cancer.
• Relapsed small cell lung cancer (SCLC) planning to receive commercial DLL3 bispecific T cell engager.
• Willing to provide informed consent.
• Willing to provide blood samples and undergo tissue biopsy at various time points throughout the study, collected in concurrence with treatment cycles and/or imaging visits
• Patients with multiple primary malignancies, recurrent lung cancer, or mixed histology are not excluded.
• Patients who have contraindications or are unable to receive immunotherapy will be eligible for the study, and their samples will be used for comparison and control.

Exclusion criteria

• Prisoners or incarcerated patients
• Those with cognitive impairments lacking decision-making capacity are excluded.
• There will be no specific restrictions with respect to performance status, organ function, or prior/concurrent modes of therapy other than that the patient must be able to tolerate venipuncture and any planned interventional radiology or surgical procedures deemed necessary by their treating physicians.